Table 2.
Studies reporting rates of TERT promoter mutations in different subtypes of thyroid cancer
| No. | Study | All PTCsa | All FTCsa | CPTCa | FVPTCa | TCPTCa | PDTCa | ATCa |
|---|---|---|---|---|---|---|---|---|
| 1 | Vinagre et al. [20] | 13/169 (7.7) | 9/64 (14.1) | 3/14 (21.4) | 2/16 (12.6) | |||
| 2 | Liu et al. [21] | 30/257 (11.7) | 11/79 (13.9) | 23/178 (12.9) | 2/56 (3.6) | 4/13 (30.8) | 3/8 (37.5) | 25/54 (46.3) |
| 3 | Landa et al. [27] | 18/80 (22.5) | 30/58 (51.7) | 10/20 (50.0) | ||||
| 4 | Liu & Xing [32] | 5/111 (4.5) | 4/18 (22.2) | |||||
| 5 | Xing et al. [33] | 61/507 (12.1) | 47/383 (12.3) | 8/103 (7.8) | 5/19 (26.3) | |||
| 6 | Wang et al. [34] | 9/52 (17.3) | ||||||
| 7 | Liu et al. [35] | 46/408 (11.3) | 8/22 (36.4) | |||||
| 8 | Melo et al. [36] | 25/332 (7.5) | 12/70 (17.1) | 9/31 (29.0) | 12/36 (33.3) | |||
| 9 | Liu et al. [37] | 13/51 (25.5) | 8/36 (22.2) | 10/20 (50.0) | ||||
| 10 | Shi et al. [28] | 41/106 (38.7) | ||||||
| 11 | Gandolfi et al. [29] | 21/121 (17.4) | 6/21 (28.6) | 2/21 (9.5) | ||||
| 12 | Muzza et al. [30] | 22/182 (12.1) | 8/58 (13.8) | 12/143 (8.4) | 10/39 (25.6) | |||
| 13 | De Biase et al. [38] | 19/404 (4.7) | ||||||
| Total | 273/2622 (10.4) | 69/399 (17.3) | 88/725 (12.1) | 22/219 (10.0) | 9/32 (28.1) | 45/111 (40.5) | 100/252 (39.7) |
PTC papillary thyroid cancer, FTC follicular thyroid cancer, CPTC conventional PTC, FVPTC follicular variant PTC, TCPTC tall cell PTC, PDTC poorly differentiated thyroid cancer, ATC anaplastic thyroid cancer
aNumbers represent numbers of cases with mutations/total number of cases tested (%)